Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response

Konsta Kukkonen; Sinja Taavitsainen; Laura Huhtala; Joonas Uusi-Makela; Kirsi J. Granberg; Matti Nykter; Alfonso Urbanucci

doi:10.3390/cancers13133325

Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response

Konsta Kukkonen, Sinja Taavitsainen, Laura Huhtala, Joonas Uusi-Makela, Kirsi J. Granberg, Matti Nykter, Alfonso Urbanucci

Tays Syöpäkeskus

Tutkimustuotos: Katsausartikkeli › vertaisarvioitu

17 Sitaatiot (Scopus)

43 Lataukset (Pure)

Abstrakti

The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity, this process has the ability to mediate all defined hallmarks of cancer. In this review, we collect and assess evidence on the contribution of chromatin and epigenetic dysregulation in prostate cancer. We highlight important mechanisms leading to prostate carcinogenesis, the emergence of castration-resistance upon treatment with androgen deprivation therapy, and resistance to antiandrogens. We examine in particular the contribution of chromatin structure and epigenetics to cell lineage commitment, which is dysregulated during tumorigenesis, and cell plasticity, which is altered during tumor progression.

Alkuperäiskieli	Englanti
Artikkeli	3325
Julkaisu	Cancers
Vuosikerta	13
Numero	13
DOI - pysyväislinkit	https://doi.org/10.3390/cancers13133325
Tila	Julkaistu - heinäk. 2021
OKM-julkaisutyyppi	A2 Katsausartikkeli tieteellisessä aikakauslehdessä

Rahoitus

Funding: This study is supported by the Norwegian Cancer Society #198016-2018 (A.U.), Finnish Cultural Foundation (S.T., J.U.), Academy of Finland #312043 (M.N.), #310829 (M.N.), #333545 (K.J.G., L.H.), #317755 (K.K.), Cancer Foundation Finland (M.N., K.J.G., L.H.), Sigrid Jusélius Foundation (M.N., K.J.G., L.H.), Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (M.N., K.J.G.), Emil Aaltonen Foundation (K.J.G., L.H.), Finnish Cancer Institute (M.N.).

Julkaisufoorumi-taso

Jufo-taso 1

!!ASJC Scopus subject areas

Oncology
Cancer Research

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

Pääsy asiakirjaan

10.3390/cancers13133325Lisenssi: CC BY

cancers-13-03325Final published version, 2,08 MBLisenssi: CC BY

http://urn.fi/URN:NBN:fi:tuni-202107236326Lisenssi: CC BY

Siteeraa tätä

@article{f74cc65315ea46f68b2aec075961477a,

title = "Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response",

abstract = "The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity, this process has the ability to mediate all defined hallmarks of cancer. In this review, we collect and assess evidence on the contribution of chromatin and epigenetic dysregulation in prostate cancer. We highlight important mechanisms leading to prostate carcinogenesis, the emergence of castration-resistance upon treatment with androgen deprivation therapy, and resistance to antiandrogens. We examine in particular the contribution of chromatin structure and epigenetics to cell lineage commitment, which is dysregulated during tumorigenesis, and cell plasticity, which is altered during tumor progression.",

keywords = "Androgen receptor signaling inhibitors, Castration resistant prostate cancer, Chromatin, Chromatin regulators alterations, Chromatin-associated factors, Drug resistance, Epigenetics, Lineage commitment, Lineage plasticity, Prostate cancer",

author = "Konsta Kukkonen and Sinja Taavitsainen and Laura Huhtala and Joonas Uusi-Makela and Granberg, {Kirsi J.} and Matti Nykter and Alfonso Urbanucci",

note = "Funding Information: Funding: This study is supported by the Norwegian Cancer Society #198016-2018 (A.U.), Finnish Cultural Foundation (S.T., J.U.), Academy of Finland #312043 (M.N.), #310829 (M.N.), #333545 (K.J.G., L.H.), #317755 (K.K.), Cancer Foundation Finland (M.N., K.J.G., L.H.), Sigrid Jus{\'e}lius Foundation (M.N., K.J.G., L.H.), Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (M.N., K.J.G.), Emil Aaltonen Foundation (K.J.G., L.H.), Finnish Cancer Institute (M.N.). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jul,

doi = "10.3390/cancers13133325",

language = "English",

volume = "13",

number = "13",

}

TY - JOUR

T1 - Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response

AU - Kukkonen, Konsta

AU - Taavitsainen, Sinja

AU - Huhtala, Laura

AU - Uusi-Makela, Joonas

AU - Granberg, Kirsi J.

AU - Nykter, Matti

AU - Urbanucci, Alfonso

N1 - Funding Information: Funding: This study is supported by the Norwegian Cancer Society #198016-2018 (A.U.), Finnish Cultural Foundation (S.T., J.U.), Academy of Finland #312043 (M.N.), #310829 (M.N.), #333545 (K.J.G., L.H.), #317755 (K.K.), Cancer Foundation Finland (M.N., K.J.G., L.H.), Sigrid Jusélius Foundation (M.N., K.J.G., L.H.), Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (M.N., K.J.G.), Emil Aaltonen Foundation (K.J.G., L.H.), Finnish Cancer Institute (M.N.). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/7

Y1 - 2021/7

N2 - The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity, this process has the ability to mediate all defined hallmarks of cancer. In this review, we collect and assess evidence on the contribution of chromatin and epigenetic dysregulation in prostate cancer. We highlight important mechanisms leading to prostate carcinogenesis, the emergence of castration-resistance upon treatment with androgen deprivation therapy, and resistance to antiandrogens. We examine in particular the contribution of chromatin structure and epigenetics to cell lineage commitment, which is dysregulated during tumorigenesis, and cell plasticity, which is altered during tumor progression.

AB - The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity, this process has the ability to mediate all defined hallmarks of cancer. In this review, we collect and assess evidence on the contribution of chromatin and epigenetic dysregulation in prostate cancer. We highlight important mechanisms leading to prostate carcinogenesis, the emergence of castration-resistance upon treatment with androgen deprivation therapy, and resistance to antiandrogens. We examine in particular the contribution of chromatin structure and epigenetics to cell lineage commitment, which is dysregulated during tumorigenesis, and cell plasticity, which is altered during tumor progression.

KW - Androgen receptor signaling inhibitors

KW - Castration resistant prostate cancer

KW - Chromatin

KW - Chromatin regulators alterations

KW - Chromatin-associated factors

KW - Drug resistance

KW - Epigenetics

KW - Lineage commitment

KW - Lineage plasticity

KW - Prostate cancer

U2 - 10.3390/cancers13133325

DO - 10.3390/cancers13133325

M3 - Review Article

AN - SCOPUS:85109316046

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 13

M1 - 3325

ER -

Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response

Abstrakti

Rahoitus

Julkaisufoorumi-taso

!!ASJC Scopus subject areas

YK:n kestävän kehityksen tavoitteet

Pääsy asiakirjaan

Sormenjälki

Siteeraa tätä